- Product Details
- Performance Data
- Reviews & Citations
- Resources

Assay Type | Competition-TR-FRET |
Reactivity | Human |
Regulatory Status | RUO |
Assay Time | 1 h |
Sample volume | 10 μL |
The Human IL-5 / IL-5Rα Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human IL-5 binding to human IL-5Rα within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of human IL-5 to bind to human IL-5Rα.
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ID | Components | Size |
FRTP017-C01 | Human IL-5 R alpha Protein Europium-chelate | 100 tests/500 tests |
FRTP017-C02 | FA Labeled Human IL-5 Protein | 100 tests/500 tests |
FRTP017-C03 | Monoclonal Anti-IL-5 R alpha Antibody | 20 μg/100 tests 100 μg/500 tests |
DB-04 | TR-FRET Sample Dilution Buffer, pH7.4 | 50 mL/100 tests & 500 tests |
DB-05 | TR-FRET Detection Buffer, pH7.4 | 50 mL/100 tests & 500 tests |
This Human IL-5 / IL-5Rα Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human IL-5 R alpha and Europium-chelate labeled streptavidin as the donor and FA labeled human IL-5 as the acceptor.
— In the absence of inhibitors for human IL-5 R alpha binding to human IL-5, the donor and acceptor are in close proximity due to the binding of human IL-5 R alpha and human IL-5. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
— In the presence of inhibitors that block the binding of human IL-5 R alpha to human IL-5, the donor-acceptor interaction is disrupted, preventing FRET from occurring.
